

Press release

Synairgen plc
(‘Synairgen’ or the ‘Company’)

Notice of Annual Report and Accounts and Annual General Meeting

Southampton, UK – 14 October 2009: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma and chronic obstructive pulmonary disease (‘COPD’), announces that the Company's Annual Report and Accounts for the year ended 30 June 2009 has been posted to shareholders. A copy of the report can be found on the Company's website: www.synairgen.com.

Synairgen’s 2009 Annual General Meeting (‘AGM’) will be held at 12 noon on Wednesday 11 November 2009 at the offices of Fasken Martineau LLP, 17 Hanover Square, London W1S 1HU. The Notice of the AGM is included in the Annual Report and Accounts.

-Ends-

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer
John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

Matrix Corporate Capital

Alastair Stratton
Anu Tayal

Tel: + 44 (0) 20 3206 7000

Threadneedle Communications

Graham Herring
Josh Royston

Tel: + 44 (0) 20 7653 9850